30: From Monoclonals to Gene Therapy: Tips for Biopharma Process Development w/ Neil Templeton - Part 2
02/22/24 • 14 min
In our insightful second part of the conversation, we broaden our perspective to delve into the various modalities within the biotech industry, highlighting the unique and shared aspects of process development and scale-up.
Neil Templeton, the Director of Upstream Process Development at Solid Biosciences, passionately articulates his commitment towards making gene therapy more accessible. He does this by outlining strategic solutions to reduce the costs of development and manufacturing.
You will gain:
- A comprehensive understanding of process development's similarities and differences across biologics, vaccines, and cell and gene therapy manufacturing.
- Effective strategies aimed at reducing the costs associated with gene therapy development and manufacturing.
- Insights into how capitalizing on the expertise from the biologics sector can positively impact other fields.
To connect with Neil Templeton and learn more about his work, visit his LinkedIn profile.
LinkedIn: https://www.linkedin.com/in/neil-templeton
Next Step:
Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com
In our insightful second part of the conversation, we broaden our perspective to delve into the various modalities within the biotech industry, highlighting the unique and shared aspects of process development and scale-up.
Neil Templeton, the Director of Upstream Process Development at Solid Biosciences, passionately articulates his commitment towards making gene therapy more accessible. He does this by outlining strategic solutions to reduce the costs of development and manufacturing.
You will gain:
- A comprehensive understanding of process development's similarities and differences across biologics, vaccines, and cell and gene therapy manufacturing.
- Effective strategies aimed at reducing the costs associated with gene therapy development and manufacturing.
- Insights into how capitalizing on the expertise from the biologics sector can positively impact other fields.
To connect with Neil Templeton and learn more about his work, visit his LinkedIn profile.
LinkedIn: https://www.linkedin.com/in/neil-templeton
Next Step:
Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com
Previous Episode
29: From Monoclonals to Gene Therapy: Tips for Biopharma Process Development w/ Neil Templeton - Part 1
In this enlightening episode, we're joined by Neil Templeton, Director in Upstream Process Development at Solid Biosciences, who pulls back the curtain on the intricate world of bioprocess development and manufacturing.
Neil delves into the shifting paradigms of the industry, sharing his expert insights on overcoming the unique challenges that surface when transitioning from R&D to GMP production. This episode is packed full of invaluable knowledge that's crucial for anyone looking to succeed in this field.
Key points we discuss include:
- Strategies and solutions for overcoming the obstacles faced when transitioning from R&D to GMP production.
- The importance and application of Design of Experiment (DOE) approaches, and their role in understanding critical process parameters.
- The role of metabolite analysis in optimizing processes and ensuring their robustness.
Get connected with Neil Templeton:
LinkedIn: https://www.linkedin.com/in/neil-templeton
Next Step:
Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com
Next Episode
31: The Future of Glycoengineering: Trends Unveiled w/ Thomas Rexer - Part 1
Get ready for a crash course in glycoengineering as Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, breaks down the significance of modifying glycans in biopharmaceuticals.
Explore the science behind glycoengineering and its potential to enhance the properties of therapeutic proteins.
Key Insights:
- Unlock new frontiers in glycoengineering
- Explore the potential of glycoengineering to revolutionize biopharmaceuticals
- Ensure seamless integration of glycoengineering into production processes
Don't miss this episode as Thomas unveils the trends that will shape the future of glycoengineering, offering actionable insights for scientists, entrepreneurs, and biotech enthusiasts alike.
Connect with Thomas Rexer:
LinkedIn: https://www.linkedin.com/in/thomas-rexer
Website: www.eversyn.de
Next Step:
Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/smart-biotech-scientist-master-bioprocess-cmc-development-biologics-ma-320725/30-from-monoclonals-to-gene-therapy-tips-for-biopharma-process-develop-46955103"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to 30: from monoclonals to gene therapy: tips for biopharma process development w/ neil templeton - part 2 on goodpods" style="width: 225px" /> </a>
Copy